Lupin, Medicis Reach Deal Over Generic Solodyn

Law360, New York (July 25, 2011, 6:18 PM EDT) -- Lupin Ltd. said Monday it had reached a deal with Medicis Pharmaceutical Corp. to make a generic version of the acne drug Solodyn and to start a development collaboration worth an initial $20 million, resolving patent litigation in Maryland federal court.

The agreement allows Mumbai-based Lupin to sell a generic version of Solodyn in three different doses as early as November, according to the company. In a separate agreement, Lupin said it would join forces with Medicis to use its proprietary formulation technology to develop new...
To view the full article, register now.